Literature DB >> 14706990

Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin.

Moises Diago, Tarek Hassanein, Juan Rodés, Andrew M Ackrill, Farhad Sedarati.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14706990     DOI： 10.7326/0003-4819-140-1-200401060-00035

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  11 in total

Review 1.  Current therapy for hepatitis C.

Authors:  Mireen Friedrich-Rust; Stefan Zeuzem; Christoph Sarrazin
Journal:  Int J Colorectal Dis       Date:  2005-09-21       Impact factor: 2.571

Review 2.  Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6.

Authors:  Vasilios Papastergiou; Stylianos Karatapanis
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

Review 3.  [Individualised treatment of chronic hepatitis C].

Authors:  S Zeuzem
Journal:  Internist (Berl)       Date:  2006-06       Impact factor: 0.743

4.  Pegylated alpha interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection.

Authors:  Tawhida Yassin Abdel Ghaffar; Suzan El Naghy; Hatem El Sebaie; Magda El Monaiery; Aisha Yassin Abdel Ghaffar
Journal:  Indian J Pediatr       Date:  2009-11-04       Impact factor: 1.967

5.  Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin.

Authors:  Brittany E Yee; Nghia H Nguyen; Bing Zhang; Philip Vutien; Carrie R Wong; Glen A Lutchman; Mindie H Nguyen
Journal:  Eur J Gastroenterol Hepatol       Date:  2014-11       Impact factor: 2.566

6.  Management of chronic hepatitis C: consensus guidelines.

Authors:  Morris Sherman; Stephen Shafran; Kelly Burak; Karen Doucette; Winnie Wong; Nigel Girgrah; Eric Yoshida; Eberhard Renner; Philip Wong; Marc Deschênes
Journal:  Can J Gastroenterol       Date:  2007-06       Impact factor: 3.522

Review 7.  Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection.

Authors:  Susan J Keam; Risto S Cvetković
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  European vs. Egyptian HCV-4 patients with elevated baseline HCV RNA, treated with PEG-IFN-α2a and ribavirin: the role of rapid and early virologic response.

Authors:  Dimitrios Dimitroulopoulos; Ioannis Elefsiniotis; Christos Pavlidis; Dimitrios Xinopoulos; Klisthenis Tsamakidis; Stamatina Patsavela; Dimitrios Kypreos; Ageliki Ferderigou; Dimitrios Korkolis; Sotirios Koutsounas; Georgios Saroglou; Emmanouil Paraskevas
Journal:  Hepat Mon       Date:  2010-09-01       Impact factor: 0.660

9.  Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis.

Authors:  Brittany E Yee; Nghia H Nguyen; Bing Zhang; Derek Lin; Philip Vutien; Carrie R Wong; Glen A Lutchman; Mindie H Nguyen
Journal:  BMJ Open Gastroenterol       Date:  2015-07-09

10.  Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.

Authors:  Hamad Al Ashgar; Ahmed Helmy; Mohamed Q Khan; Khalid Al Kahtani; Mohammed Al Quaiz; Mohammed Rezeig; Ingvar Kagevi; Abdullah Alshehri; Abdullah Al Kalbani; Khalid Al Swat; Salim Dahab; Naser Elkum; Mohammed Al Fadda
Journal:  Ann Saudi Med       Date:  2009 Jan-Feb       Impact factor: 1.526
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.